Concepedia
Statistics
Publications
20
Citations
6.1K
H-Index
Active since
2007
Affiliations
GlaxoSmithKline (United States)(Current)
University Hospital Schleswig-Holstein
University of Lübeck
Memorial Sloan Kettering Cancer Center
Sir Charles Gairdner Hospital
Vicki Goodman is an author at GlaxoSmithKline (United States) specializing in medicine, oncology, and pharmacology.
Publications per year
2007–2020
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild, Jean‐Jacques Grob, Lev Demidov et al. · The Lancet · 2012 · 3K citations
Medicine, Oncology, Pharmacology +11
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
Georgina V. Long, Uwe Trefzer, Michael A. Davies et al. · The Lancet Oncology · 2012 · 908 citations
Medicine, Oncology, Pharmacology +12
Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
Paolo A. Ascierto, David R. Minor, Antoni Ribas et al. · Journal of Clinical Oncology · 2013 · 427 citations
Medicine, Oncology, Pharmacology +16
Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell Carcinoma
Edwin P. Rock, Vicki Goodman, Janet Jiang et al. · The Oncologist · 2007 · 246 citations · Full text
Medicine, Pharmacology, Pharmacotherapy +14
Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate
Michael H. Brave, Vicki Goodman, Edvardas Kaminskas et al. · Clinical Cancer Research · 2008 · 242 citations
Medicine, Hematology, Pharmacology +15
1–5 of 20